We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert Panel Defers Decision on Merck’s Keytruda for New Breast Cancer Indication
Expert Panel Defers Decision on Merck’s Keytruda for New Breast Cancer Indication
A 10-member FDA advisory committee voted unanimously yesterday to defer a decision to recommend Merck’s blockbuster oncology drug Keytruda (pembrolizumab) for a new breast cancer indication and to await more data from a late stage trial.